And now, back by popular demand ... 8 medical sentences that could benefit from a little editing.
Phase 3 VESALIUS-CV Trial Demonstrates Evolocumab Reduces Cardiovascular Events in High-Risk Adults Without Prior Heart Attack or Stroke
Evolocumab significantly reduced major cardiovascular events in high-risk patients without prior heart attack or stroke, making it the first PCSK9 inhibitor with proven benefit in both primary and secondary prevention.
Weekly Dose Podcast: Arrhythmias as Early Risk Markers, Flu Vaccine Safety, Salt Substitute Use, Preconception CT Risks, and Global Diabetes Care Gaps
Today's episode highlights arrhythmias as CVD risk markers, influenza vaccine safety, salt substitute use, preconception CT risks, and global diabetes gaps.
Novartis' Oral Targeted BTKi Treatment Approved for Chronic Spontaneous Urticaria in Adults
Remibrutinib is the first oral BTK inhibitor for chronic spontaneous urticaria, with a dual mechanism of action that blocks 2 key autoimmune mechanisms.
Weekly Dose Podcast: Depression Risk After Chronic Illness, Vaginal Estradiol Safety, GLP-1 Updates, Cancer Risk Reduction, and Cardiovascular Outcomes
Today's episode covers depression risk after chronic illness, vaginal estradiol safety, GLP-1 updates, cancer risk, and cardiovascular outcomes.
FMX 2025: American Academy of Family Physicians Main Stage Speakers
This year, the FMX Main Stage presenters will be led by Vivek H Murthy, the 21st US Surgeon General. Learn more about him and the 2 other inspiring guests.
FDA Grants Fast Track Designation to Anti-MTBR Tau Antibody BMS-986446 for Alzheimer Disease
The FDA has granted fast track designation to BMS-986446, an anti–microtubule binding region tau antibody in phase 2 trials for early Alzheimer disease.